Fig. 6: Practical algorithm indicating when BCR::ABL1 TKD mutation testing should be performed based on BCR::ABL1 transcript levels at each timepoint during therapy.
For example, at 6 months on treatment a patient who has not achieved (N) ≤ 1% BCR::ABL1IS should be considered for BCR::ABL1 TKD testing. If ≤ 1% BCR::ABL1IS has been achieved (Y) then TKD testing is not required and the patient should be reassessed at 12 months. TKD mutation testing is not generally recommended for any patient with ≤ 0.1% BCR::ABL1IS, in part because the sensitivity of detection is low and amplification of the large fragment required for BCR::ABL1-specific mutation detection may be challenging.
